HR | 95% CI | |
---|---|---|
BE surveillance diagnosing EGD vs non-surveillance | ||
All EAC cases (n=207/424; 81/209 surveillance and 126/215 non-surveillance) | ||
Unadjusted | 0.52 | 0.39 to 0.69 |
Adjusted* (without stage or treatment) | 0.49 | 0.37 to 0.66 |
Adjusted (including stage) | 0.76 | 0.55 to 1.06 |
Adjusted (including stage and treatment) | 0.73 | 0.52 to 1.01 |
EAC-related mortality (n=187/424; 71/209 surveillance and 116/215 non-surveillance) | ||
Unadjusted | 0.50 | 0.37 to 0.67 |
Adjusted* (without stage or treatment) | 0.47 | 0.35 to 0.64 |
Adjusted (including stage) | 0.75 | 0.53 to 1.05 |
Adjusted (including stage and treatment) | 0.72 | 0.51 to 1.01 |
*Adjusted for year of EAC diagnosis, age, race, propensity of EGD, comorbidity score, total number of VA visit and GI clinic visit.
EGD, oesophagogastroduodenoscopy; VA, Veteran Affairs.